MedPath

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Completed
Conditions
Parkinson Disease
Interventions
Registration Number
NCT01361009
Lead Sponsor
Boehringer Ingelheim
Brief Summary

This is an open-label, multicenter, non-interventional, prospective observational study. we collect the safety information of pramipexole over 12w treatment. Parkinson disease patients with different severity who have already used pramipexole could be observed in this study. In the whole observation period, treatment decision was determined by physician and patient completely. The safety endpoint is AE(Adverse Event), SAE(Serious Adverse Event), patient withdraw, laboratory test.

Detailed Description

Purpose:

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2017
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
pramipexole grouppramipexoleIt's a open-label, non-intervention,observation post marketing surveillance to observe the safety and efficacy of pramipexole in real world.
Primary Outcome Measures
NameTimeMethod
Incidence of AE/SAE12 weeks

The percentage of adverse events or serious adverse events occurring under Pramipexole mono- or combination therapy with other medication in this study.

Secondary Outcome Measures
NameTimeMethod
The Dosage Related Information of Pramipexole at Baselinebaseline

At enrollment, the distribution of patients in 3 pramipexole dosage categories.

Patient Global Impression(PGI) at Visit 1(Baseline) and Visit 3(at the End of Study)Baseline (Visit 1) and 12 weeks (Visit 3)

Patient Global Impression (PGI) scale, ranging from 1 (excellent) to 7 (extremely poor), including 1(excellent), 2(very good), 3(good), 4(no change), 5(poor), 6(very poor) and 7(extremely poor).

The Dosage Related Information of Pramipexole at the End of Study12 weeks

At the end of study, the distribution of patients in 3 pramipexole dosage categories.

Trial Locations

Locations (103)

Boehringer Ingelheim Investigational Site 52

🇨🇳

Suzhou, China

Boehringer Ingelheim Investigational Site 57

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 60

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 67

🇨🇳

Changchun, China

Boehringer Ingelheim Investigational Site 99

🇨🇳

Chongqing, China

Boehringer Ingelheim Investigational Site 78

🇨🇳

Haerbin, China

Boehringer Ingelheim Investigational Site 28

🇨🇳

Hangzhou, China

Boehringer Ingelheim Investigational Site 31

🇨🇳

Hangzhou, China

Boehringer Ingelheim Investigational Site 32

🇨🇳

Hangzhou, China

Boehringer Ingelheim Investigational Site 38

🇨🇳

Hefei, China

Boehringer Ingelheim Investigational Site 39

🇨🇳

Jinan, China

Boehringer Ingelheim Investigational Site 92

🇨🇳

Shantou, China

Boehringer Ingelheim Investigational Site 74

🇨🇳

Shenyang, China

Boehringer Ingelheim Investigational Site 51

🇨🇳

Suzhou, China

Boehringer Ingelheim Investigational Site 70

🇨🇳

Tianjin, China

Boehringer Ingelheim Investigational Site 7

🇨🇳

Wuhan, China

Boehringer Ingelheim Investigational Site 102

🇨🇳

Xian, China

Boehringer Ingelheim Investigational Site 103

🇨🇳

Xian, China

Boehringer Ingelheim Investigational Site 58

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 54

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 55

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 56

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 61

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 12

🇨🇳

Changsh, China

Boehringer Ingelheim Investigational Site 62

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 65

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 63

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 66

🇨🇳

Changchun, China

Boehringer Ingelheim Investigational Site 64

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 13

🇨🇳

Changsh, China

Boehringer Ingelheim Investigational Site 14

🇨🇳

Changsh, China

Boehringer Ingelheim Investigational Site 15

🇨🇳

Changsh, China

Boehringer Ingelheim Investigational Site 16

🇨🇳

Changsh, China

Boehringer Ingelheim Investigational Site 94

🇨🇳

Chendu, China

Boehringer Ingelheim Investigational Site 95

🇨🇳

Chendu, China

Boehringer Ingelheim Investigational Site 100

🇨🇳

Chongqing, China

Boehringer Ingelheim Investigational Site 72

🇨🇳

Dalian, China

Boehringer Ingelheim Investigational Site 101

🇨🇳

Chongqing, China

Boehringer Ingelheim Investigational Site 97

🇨🇳

Chongqing, China

Boehringer Ingelheim Investigational Site 98

🇨🇳

Chongqing, China

Boehringer Ingelheim Investigational Site 71

🇨🇳

Dalian, China

Boehringer Ingelheim Investigational Site 79

🇨🇳

Daqing, China

Boehringer Ingelheim Investigational Site 35

🇨🇳

Fuzhou, China

Boehringer Ingelheim Investigational Site 36

🇨🇳

Fuzhou, China

Boehringer Ingelheim Investigational Site 37

🇨🇳

Fuzhou, China

Boehringer Ingelheim Investigational Site 80

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 81

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 82

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 83

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 84

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 85

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 86

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 87

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 88

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 89

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 90

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 91

🇨🇳

Guangzhou, China

Boehringer Ingelheim Investigational Site 77

🇨🇳

Haerbin, China

Boehringer Ingelheim Investigational Site 29

🇨🇳

Hangzhou, China

Boehringer Ingelheim Investigational Site 30

🇨🇳

Hangzhou, China

Boehringer Ingelheim Investigational Site 40

🇨🇳

Jinan, China

Boehringer Ingelheim Investigational Site 53

🇨🇳

Nanchang, China

Boehringer Ingelheim Investigational Site 96

🇨🇳

Luzhou, China

Boehringer Ingelheim Investigational Site 49

🇨🇳

Nantong, China

Boehringer Ingelheim Investigational Site 43

🇨🇳

Qingdao, China

Boehringer Ingelheim Investigational Site 46

🇨🇳

Nanjing, China

Boehringer Ingelheim Investigational Site 17

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 18

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 19

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 20

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 21

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 22

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 23

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 24

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 25

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 26

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 27

🇨🇳

Shanghai, China

Boehringer Ingelheim Investigational Site 73

🇨🇳

Shenyang, China

Boehringer Ingelheim Investigational Site 75

🇨🇳

Shenyang, China

Boehringer Ingelheim Investigational Site 76

🇨🇳

Shenyang, China

Boehringer Ingelheim Investigational Site 93

🇨🇳

Shenzhen, China

Boehringer Ingelheim Investigational Site 2

🇨🇳

Shijiazhuang, China

Boehringer Ingelheim Investigational Site 3

🇨🇳

Shijiazhuang, China

Boehringer Ingelheim Investigational Site 6

🇨🇳

Shiyan, China

Boehringer Ingelheim Investigational Site 1

🇨🇳

Taiyuan, China

Boehringer Ingelheim Investigational Site 68

🇨🇳

Tianjin, China

Boehringer Ingelheim Investigational Site 69

🇨🇳

Tianjin, China

Boehringer Ingelheim Investigational Site 41

🇨🇳

Weifang, China

Boehringer Ingelheim Investigational Site 33

🇨🇳

Wenzhou, China

Boehringer Ingelheim Investigational Site 10

🇨🇳

Wuhan, China

Boehringer Ingelheim Investigational Site 11

🇨🇳

Wuhan, China

Boehringer Ingelheim Investigational Site 8

🇨🇳

Wuhan, China

Boehringer Ingelheim Investigational Site 9

🇨🇳

Wuhan, China

Boehringer Ingelheim Investigational Site 50

🇨🇳

Wuxi, China

Boehringer Ingelheim Investigational Site 34

🇨🇳

Xiamen, China

Boehringer Ingelheim Investigational Site 42

🇨🇳

Yantai, China

Boehringer Ingelheim Investigational Site 5

🇨🇳

Zhengzhou, China

Boehringer Ingelheim Investigational Site 4

🇨🇳

Zhengzhou, China

Boehringer Ingelheim Investigational Site 59

🇨🇳

Beijing, China

Boehringer Ingelheim Investigational Site 44

🇨🇳

Nanjing, China

Boehringer Ingelheim Investigational Site 45

🇨🇳

Nanjing, China

Boehringer Ingelheim Investigational Site 47

🇨🇳

Nanjing, China

Boehringer Ingelheim Investigational Site 48

🇨🇳

Nanjing, China

© Copyright 2025. All Rights Reserved by MedPath